Metabonomics: A Useful Tool for the Future Surgeon

被引:58
|
作者
Goldsmith, Paul [2 ]
Fenton, Hayley [1 ]
Morris-Stiff, Gareth [2 ]
Ahmad, Niaz [2 ]
Fisher, Julie [1 ]
Prasad, K. Rajendra [2 ]
机构
[1] Univ Leeds, Sch Chem, Leeds LS9 2JT, W Yorkshire, England
[2] St James Univ Hosp, Hepatopancreatobiliary & Transplant Unit, Leeds, W Yorkshire, England
关键词
metabonomics; nuclear magnetic resonance spectroscopy; mass spectrometry; proteomics biomarkers; surgery; MAGNETIC-RESONANCE-SPECTROSCOPY; NMR-BASED METABOLOMICS; BREAST-CANCER TISSUE; PATTERN-RECOGNITION; RAT URINE; LIQUID-CHROMATOGRAPHY; H-1-NMR SPECTROSCOPY; NEPHROTOXIC LESIONS; TUMORS DEFICIENT; EX-VIVO;
D O I
10.1016/j.jss.2009.03.003
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background. In the past decade or so, a range of technologies have emerged that have shown promise in increasing our understanding of disease processes and progression. These advances are referred to as the "omics" technologies; genomics, transcriptomics, and proteomics. More recently, another "omics" approach has come to the fore: metabonomics, and this technology has the potential for significant clinical impact. Metabonomics refers to the analysis of the metabolome, that is, the metabolic profile of a system. The advantage of studying the metabolome is that the end points of biological events are elucidated. Results. Although still in its infancy, the metabonomics approach has shown immense promise in areas as diverse as toxicology studies to the discovery of biomarkers of disease. It has also been applied to studies of both renal and hepatic transplants. Metabolome analysis may be conducted on a variety of biological fluids and tissue types and may utilize a number of different technology platforms, mass spectrometry (MS) and nuclear magnetic resonance (NMR) spectroscopy being the most popular. In this review, we cover the background to the evolution of metabonomics and its applications with particular emphasis on clinical applications. Conclusions. We conclude with the suggestion that metabonomics offers a platform for further biomarker development, drug development, and in the field of medicine. (C) 2010 Elsevier Inc. All rights reserved.
引用
收藏
页码:122 / 132
页数:11
相关论文
共 50 条
  • [41] The surgeon for the future and implications for training
    Davidson, PM
    ANZ JOURNAL OF SURGERY, 2002, 72 (11) : 822 - 828
  • [42] The interventional cardiovascular surgeon—the future
    Mohammed Idhrees
    Hamdulay Zainulabedin
    Gunturu Varun
    Indian Journal of Thoracic and Cardiovascular Surgery, 2024, 40 : 116 - 118
  • [43] FUTURE CAREER OF THE YOUNG SURGEON
    GRUWEZ, JA
    SMETS, D
    ACTA CHIRURGICA BELGICA, 1987, 87 (01) : 54 - 57
  • [44] Future of Surgery and Shrinking Surgeon
    Khanna, Ajay K.
    Khanna, Rahul
    INDIAN JOURNAL OF SURGERY, 2011, 73 (02) : 87 - 89
  • [45] TOTAL PARATHYROIDECTOMY AND FOREARM AUTOTRANSPLANTATION FOR CHRONIC-RENAL-FAILURE - A USEFUL TOOL FOR THE GENERAL SURGEON IN PRIVATE-PRACTICE
    WHITE, KS
    WILKINSON, CA
    NIXON, WP
    ALMKUIST, RD
    SOUTHERN MEDICAL JOURNAL, 1986, 79 (07) : 844 - 846
  • [46] Both the nomogram and the score system can represent an useful tool especially in those cases where the complication is foreseen by the surgeon
    Mazzucchi, Eduardo
    INTERNATIONAL BRAZ J UROL, 2022, 48 (05): : 828 - 829
  • [47] Separation Science in the Context of Metabonomics: Current Platforms and Future Trends
    Wang Jiangshan
    Kong Hongwei
    Lu Xin
    Zhao Xinjie
    Xu Guowang
    PROGRESS IN CHEMISTRY, 2009, 21 (11) : 2388 - 2396
  • [48] Contemporary issues on the role of metabonomics as a tool for preclinical safety assessment.
    Robertson, DG
    Reily, MD
    CHEMICAL RESEARCH IN TOXICOLOGY, 2004, 17 (12) : 1783 - 1783
  • [49] Evaluation of Margin Index for Prediction of Residual Disease After Breast-Conserving Surgery: Can It Be a Useful Tool for the Breast Surgeon?
    Edwards, Claire
    Margenthaler, Julie
    Freedman, Gary
    Czerniecki, Brian
    Tchou, Julia
    Lin, Lillie
    Gao, Feng
    Fisher, Carla
    ANNALS OF SURGICAL ONCOLOGY, 2013, 20 : 39 - 39
  • [50] Contemporary issues on the role of metabonomics as a tool for preclinical safety assessment.
    Robertson, DG
    Reily, MD
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U394 - U394